Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide.Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer.PGDx was founded in 2010 by Luis Diaz and Victor Velculescu to help bring novel diagnostic approaches to patients with cancer. They are internationally recognized leaders in cancer genomics who have extensive experience in the application of innovative genomic technologies for drug development and clinical practice.Named a 2019 Top Workplace by The Baltimore SunNamed a 2018 winner of the Best Place to Work by the Business Intelligence Group

Cancer Genetics DNA-based Cancer Diagnostics Whole Exome Sequencing Whole Genome Seqeuencing Targeted Cancer Gene Sequencing Bioinformatics Oncology IVD Whole Genome Sequencing Precision Medicine Next-Generation Sequencing Liquid Biopsy Tissue Data Interpretation Analysis Pharma Partnering CAP/CLIA NGS Diagnostics B2B BioTech/Drugs Commercial Physical Research Biotechnology